KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial

MT Newswires Live2025-03-25

KalVista Pharmaceuticals (KALV) said Tuesday it has finished enrolling participants in the Konfident-KID clinical study of experimental oral plasma kallikrein inhibitor sebetralstat for children aged two to 11 with hereditary angioedema.

Strong demand led the company to enroll about 36 participants instead of the original 24, reaching the recruitment goal a year ahead of schedule, the company said.

Initial findings are expected later in this year, while the company plans to submit a supplemental New Drug Application by mid-2026, it added.

The trial, spanning seven countries in North America, Europe, and Asia, aims to gather safety, pharmacokinetic, and efficacy data for up to one year, according to the company.

Shares of the company were down about 2% in recent trading.

Price: 12.01, Change: -0.24, Percent Change: -1.96

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522005335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522005335","market":"us","top_or_hot":-1,"title":"KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial","media":"MT Newswires Live","content":"<html><body><p> KalVista Pharmaceuticals (KALV) said Tuesday it has finished enrolling participants in the Konfident-KID clinical study of experimental oral plasma kallikrein inhibitor sebetralstat for children aged two to 11 with hereditary angioedema.</p><p>Strong demand led the company to enroll about 36 participants instead of the original 24, reaching the recruitment goal a year ahead of schedule, the company said.</p><p>Initial findings are expected later in this year, while the company plans to submit a supplemental New Drug Application by mid-2026, it added.</p><p>The trial, spanning seven countries in North America, Europe, and Asia, aims to gather safety, pharmacokinetic, and efficacy data for up to one year, according to the company.</p><p>Shares of the company were down about 2% in recent trading.</p><p>Price: 12.01, Change: -0.24, Percent Change: -1.96</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-25 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> KalVista Pharmaceuticals (KALV) said Tuesday it has finished enrolling participants in the Konfident-KID clinical study of experimental oral plasma kallikrein inhibitor sebetralstat for children aged two to 11 with hereditary angioedema.</p><p>Strong demand led the company to enroll about 36 participants instead of the original 24, reaching the recruitment goal a year ahead of schedule, the company said.</p><p>Initial findings are expected later in this year, while the company plans to submit a supplemental New Drug Application by mid-2026, it added.</p><p>The trial, spanning seven countries in North America, Europe, and Asia, aims to gather safety, pharmacokinetic, and efficacy data for up to one year, according to the company.</p><p>Shares of the company were down about 2% in recent trading.</p><p>Price: 12.01, Change: -0.24, Percent Change: -1.96</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522005335","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522005335","pubTimestamp":1742913950,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"KalVista Pharmaceuticals  said Tuesday it has finished enrolling participants in the Konfident-KID clinical study of experimental oral plasma kallikrein inhibitor sebetralstat for children aged two to 11 with hereditary angioedema.Strong demand led the company to enroll about 36 participants instead of the original 24, reaching the recruitment goal a year ahead of schedule, the company said.Initial findings are expected later in this year, while the company plans to submit a supplemental New Drug Application by mid-2026, it added.The trial, spanning seven countries in North America, Europe, and Asia, aims to gather safety, pharmacokinetic, and efficacy data for up to one year, according to the company.Shares of the company were down about 2% in recent trading.Price: 12.01, Change: -0.24, Percent Change: -1.96","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KALV":"Kalvista Pharmaceuticals Inc"},"translate_title":"KalVista Pharmaceuticals提前完成儿科遗传性血管性水肿试验的参与者招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"KalVista Pharmaceuticals (KALV) said Tuesday it has finished enrolling participants in the Konfident-KID clinical study of experimental oral plasma kallikrein inhibitor sebetralstat for children aged two to 11 with hereditary angioedema.Strong demand led the company to enroll about 36 participants instead of the original 24, reaching the recruitment goal a year ahead of schedule, the company said.Initial findings are expected later in this year, while the company plans to submit a supplemental New Drug Application by mid-2026, it added.The trial, spanning seven countries in North America, Europe, and Asia, aims to gather safety, pharmacokinetic, and efficacy data for up to one year, according to the company.Shares of the company were down about 2% in recent trading.Price: 12.01, Change: -0.24, Percent Change: -1.96","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522005335","isCrawlerRequest":true}